International Assets Investment Management LLC Sells 1,338 Shares of Eli Lilly and Company $LLY

Key Points

• International Assets Investment Management LLC reduced its holdings in Eli Lilly and Company by 7.0% in Q2, selling 1,338 shares, leaving them with 17,709 shares worth approximately $13.8 million.
• Several institutional investors, including Precedent Wealth Partners LLC and Duquesne Family Office LLC, have increased their stakes in Eli Lilly during the same quarter, indicating continued interest in the company.
• Recent earnings showed Eli Lilly reporting $6.31 earnings per share, surpassing estimates, and the company set a fiscal year 2025 guidance of 21.75-23.00, showing optimism for future growth.

International Assets Investment Management LLC lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 7.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,709 shares of the company's stock after selling 1,338 shares during the quarter. Eli Lilly and Company comprises about 0.7% of International Assets Investment Management LLC's investment portfolio, making the stock its 18th biggest position. International Assets Investment Management LLC's holdings in Eli Lilly and Company were worth $13,805,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Precedent Wealth Partners LLC grew its stake in Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock valued at $229,000 after buying an additional 39 shares during the last quarter. Capital Advisors Inc. OK grew its stake in Eli Lilly and Company by 6.8% in the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock valued at $5,260,000 after buying an additional 429 shares during the last quarter. Family CFO Inc acquired a new position in Eli Lilly and Company in the 2nd quarter valued at $54,000. Duquesne Family Office LLC grew its stake in Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock valued at $78,321,000 after buying an additional 32,640 shares during the last quarter. Finally, Corient IA LLC acquired a new position in Eli Lilly and Company in the 1st quarter valued at $570,000. Institutional investors own 82.53% of the company's stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock worth $2,894,841 in the last 90 days. 0.13% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on LLY shares. UBS Group lowered their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Wall Street Zen downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 20th. Erste Group Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Tuesday, October 14th. Leerink Partners restated a "market perform" rating and set a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Finally, Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price objective on the stock. in a report on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average target price of $939.12.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $803.53 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm's 50-day simple moving average is $753.09 and its 200-day simple moving average is $765.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The firm has a market cap of $760.51 billion, a P/E ratio of 52.52, a price-to-earnings-growth ratio of 1.15 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the business earned $3.92 EPS. The firm's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.